Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | NPC1 | O15118 | 6/20 | 1.00 |
| ▸ | HTT | P42858 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | GAA | P10253 | 2/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | KLK7 | P49862 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | CA12 | O43570 | 2/20 | 0.65 |
| ▸ | CA1 | P00915 | 2/20 | 0.65 |
| ▸ | CA2 | P00918 | 2/20 | 0.65 |
| ▸ | CA9 | Q16790 | 2/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.64 |
| ▸ | RECQL | P46063 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27193044 | 0.88 | RAB9A (0.77) | RAB9ASMN1; SMN2NPC1HTTLMNA | |
| SCHEMBL6823516 | 0.85 | SMN1; SMN2 (0.74) | RAB9ASMN1; SMN2NPC1HTTLMNA | |
| SCHEMBL29757933 | 0.85 | SMN1; SMN2 (0.74) | RAB9ASMN1; SMN2NPC1HTTLMNA | |
| SCHEMBL24272365 | 0.85 | SMN1; SMN2 (0.74) | RAB9ASMN1; SMN2NPC1HTTLMNA | |
| SCHEMBL5595167 | 0.85 | SMN1; SMN2 (0.74) | RAB9ASMN1; SMN2NPC1HTTLMNA | |
| SCHEMBL21834398 | 0.84 | NPC1 (1.00) | RAB9ASMN1; SMN2NPC1HTTLMNA | |
| SCHEMBL16946643 | 0.84 | MAPT (0.76) | RAB9ASMN1; SMN2NPC1HTTLMNA | |
| Water SCHEMBL30430295 | 0.83 | HTT (0.97) | RAB9ASMN1; SMN2NPC1HTTLMNA | |
| SCHEMBL21834403 | 0.82 | NPC1 (0.81) | RAB9ASMN1; SMN2NPC1HTTLMNA | |
| SCHEMBL22926423 | 0.82 | HTT (0.70) | RAB9ASMN1; SMN2NPC1HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10344032-B2 | Agents for treating neurogenic inflammation and neuropathic hyperalgesia related disorders | PÉCSI TUDOMÁNYEGYETEM (HU) | 2019-07-09 | — | — | US | claimed |
| EP-3194399-B1 | NEW AGENTS FOR TREATING NEUROGENIC INFLAMMATION AND NEUROPATHIC HYPERALGESIA RELATED DISORDERS | PECSI TUDOMANYEGYETEM (HU) | 2019-04-10 | — | — | EP | claimed |
| US-20170260187-A1 | NEW AGENTS FOR TREATING NEUROGENIC INFLAMMATION AND NEUROPATHIC HYPERALGESIA RELATED DISORDERS | PÉCSI TUDOMÁNYEGYETEM (HU) | 2017-09-14 | — | — | US | claimed |
| EP-3194399-A1 | NEW AGENTS FOR TREATING NEUROGENIC INFLAMMATION AND NEUROPATHIC HYPERALGESIA RELATED DISORDERS | Pécsi Tudományegyetem (HU) | 2017-07-26 | — | — | EP | claimed |
| WO-2016042349-A1 | NEW AGENTS FOR TREATING NEUROGENIC INFLAMMATION AND NEUROPATHIC HYPERALGESIA RELATED DISORDERS | PÉCSI TUDOMÁNYEGYETEM (HU) | 2016-03-24 | — | — | WO | claimed |
| US-10344032-B2 | Agents for treating neurogenic inflammation and neuropathic hyperalgesia related disorders | PÉCSI TUDOMÁNYEGYETEM (HU) | 2019-07-09 | — | — | US | disclosed |
| EP-3194399-B1 | NEW AGENTS FOR TREATING NEUROGENIC INFLAMMATION AND NEUROPATHIC HYPERALGESIA RELATED DISORDERS | PECSI TUDOMANYEGYETEM (HU) | 2019-04-10 | — | — | EP | disclosed |
| US-20170260187-A1 | NEW AGENTS FOR TREATING NEUROGENIC INFLAMMATION AND NEUROPATHIC HYPERALGESIA RELATED DISORDERS | PÉCSI TUDOMÁNYEGYETEM (HU) | 2017-09-14 | — | — | US | disclosed |
| EP-3194399-A1 | NEW AGENTS FOR TREATING NEUROGENIC INFLAMMATION AND NEUROPATHIC HYPERALGESIA RELATED DISORDERS | Pécsi Tudományegyetem (HU) | 2017-07-26 | — | — | EP | disclosed |
| WO-2016042349-A1 | NEW AGENTS FOR TREATING NEUROGENIC INFLAMMATION AND NEUROPATHIC HYPERALGESIA RELATED DISORDERS | PÉCSI TUDOMÁNYEGYETEM (HU) | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10344032-B2 | Agents for treating neurogenic inflammation and neuropathic hyperalgesia related disorders | TRPV1, P2RX3, P2RX7 | RAB9A 3374/4885SMN1; SMN2 559/4885NPC1 984/4885 |
| US-20170260187-A1 | NEW AGENTS FOR TREATING NEUROGENIC INFLAMMATION AND NEUROPATHIC HYPERALGESIA RELATED DISORDERS | TRPV1, P2RX3, P2RX4 | RAB9A 2980/4885SMN1; SMN2 669/4885NPC1 1136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.